The Impact of Differing Gleason Scores at Biopsy on the Odds of Upgrading and the Risk of Death from Prostate Cancer

摘要

BackgroundThe Gleason score (GS) is an established prostate cancer (PCa) prognostic factor. Whether the presence of differing GS’s at biopsy (e.g. 4 + 3 and 3 + 3), which we term ComboGS, improves the prognosis that would be predicted based on the highest GS (e.g.4 + 3) due to decreased upgrading is unknown. Therefore, we evaluated the odds of upgrading at radical prostatectomy (RP) and the risk of prostate cancer-specific mortality (PCSM) when ComboGS was present versus absent.